Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Clinical Trial ID NCT00137111

PubWeight™ 260.47‹?›

🔗 Visit the page for NCT00137111

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007 17.68
2 Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 11.30
3 Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009 10.54
4 BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008 10.12
5 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 9.89
6 Acute lymphoblastic leukaemia. Lancet 2008 8.54
7 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
8 Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 5.37
9 CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods 2011 5.34
10 Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011 4.93
11 Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009 4.89
12 Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012 4.41
13 Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009 4.35
14 Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015 4.27
15 CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011 3.72
16 The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013 3.43
17 Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 2.82
18 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009 2.72
19 Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood 2009 2.70
20 Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012 2.55
21 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2011 2.52
22 Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2010 2.37
23 The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 2015 2.34
24 Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008 2.29
25 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
26 Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015 2.20
27 A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007 2.19
28 Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol 2015 2.15
29 Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012 2.14
30 The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010 2.09
31 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
32 Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 2008 1.89
33 Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2011 1.88
34 Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011 1.85
35 Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015 1.84
36 Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2008 1.82
37 Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013 1.81
38 Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008 1.79
39 New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011 1.78
40 Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol 2013 1.76
41 Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015 1.74
42 High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011 1.68
43 PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012 1.66
44 Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 2011 1.60
45 Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010 1.57
46 Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood 2015 1.57
47 Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Phys Ther 2014 1.53
48 Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010 1.47
49 Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013 1.45
50 The Health Utilities Index 3 invalidated when completed by nurses for pediatric oncology patients. Cancer Nurs 2007 1.43
51 Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood 2015 1.42
52 Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 2012 1.41
53 Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006 1.41
54 A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006 1.40
55 ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012 1.39
56 In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 2008 1.37
57 Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011 1.34
58 ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 2010 1.34
59 A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 2013 1.32
60 Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 1.31
61 PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011 1.27
62 Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer 2010 1.26
63 Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 2015 1.26
64 Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol 2012 1.25
65 Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol 2007 1.22
66 Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2012 1.17
67 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
68 Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer 2007 1.16
69 Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012 1.15
70 Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 2010 1.15
71 Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol 2010 1.14
72 Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther 2011 1.14
73 Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014 1.10
74 Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012 1.10
75 Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013 1.10
76 ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2011 1.08
77 IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia 2011 1.08
78 Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009 1.07
79 Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 2010 1.07
80 Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008 1.06
81 A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 2014 1.04
82 A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2010 1.03
83 MRI of knee osteonecrosis in children with leukemia and lymphoma: Part 2, clinical and imaging patterns. AJR Am J Roentgenol 2006 1.02
84 NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 2015 1.02
85 Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood 2011 1.00
86 Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 2012 0.99
87 Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther 2008 0.99
88 Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia. Pediatr Blood Cancer 2011 0.96
89 Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia. AJNR Am J Neuroradiol 2009 0.96
90 A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014 0.95
91 HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 2014 0.94
92 NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016 0.93
93 Shared acquired genomic changes in zebrafish and human T-ALL. Oncogene 2011 0.93
94 Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 2016 0.93
95 Evidence for age as a modifier of genetic associations for lipid levels. Ann Hum Genet 2011 0.92
96 Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform 2011 0.91
97 Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2014 0.90
98 Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nat Commun 2015 0.89
99 Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. PLoS Genet 2015 0.87
100 Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood 2015 0.87
Next 100